Journals / Selçuk Tıp Dergisi / 2009 / Cilt: 25 - Sayı: 3

Management of high risk essential thrombocythemia in pregnant with recurrent pregnancy loss

Tekrarlayan gebelik kaybı bulunan yüksek riskli esansiyel trombositemili gebede tedavi

Pages
167–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, treatment with IFN-α, aspirin and LMWH are safe and improve pregnancy outcomes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Essantial Thrombocythemia (ET) is a disease characterized by an increased platelets count, megakaryocyte hyperplasia and increased thrombotic or hemorrhagic events.
📊
Key Findings & Data:ET is frequent in women and 15-20% of patients with ET are diagnosed in childbearing age.
💡
Conclusion & Impact:Thus, treatment with IFN-α, aspirin and LMWH are safe and improve pregnancy outcomes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Essantial Thrombocythemia (ET) is a disease characterized by an increased platelets count, megakaryocyte hyperplasia and increased thrombotic or hemorrhagic events. ET is frequent in women and 15-20% of patients with ET are diagnosed in childbearing age. Pregnancy loss is more in patients with ET than normal population. Early pregnancy loss occurs in 1/3 of patients with ET. We present a women, with ET complicated with portal vein thrombosis who had 3 early and 1 late pregnancy loss with hydroxyurea treatment. She had live birth after treatment with interferonalfa (IFN-α) and low molecular weight heparin (LMWH). Aims of treatment of pregnant women with ET prevent of maternal complications and pregnancy loss due to vasooclusive events. Thus, treatment with IFN-α, aspirin and LMWH are safe and improve pregnancy outcomes.

Özet

Esansiyel trombositemia (ET) tormbositoz, megakaryosit hiperplazisi, kanama veya tombozlar ile karaekterize bir hastalıktır. ET kadınlarda daha sık görülmektedir ve yaklaşık %15-20’sini doğurganlık çağındaki hastalar oluşturmaktadır. ET’li kadınlarda gebelik kayıpları normal popülasyona göre daha sık görülmektedir. Yaklaşık 1/3’ü erken gebelik kayıpları şeklindedir. Hidroksiüre tedavisi altında 3 adet erken gebelik kaybı, 1 adet ölü doğum gerçekleştiren, portal ven trombozu bulunan yüksek riskli bir ET hastasında interferon-alfa (IFN-α) ve düşük moleküler ağırlıklı heparin (DMAH) tedavisi ile miadında sağlıklı, canlı doğum gerçekleştiren bir olgu sunulmuştur. ET’li gebelerde tedavi amacı maternal komplikasyonların ve fetal kayıplara neden olacak vazooklüsiv olayların önlenmesi olmalıdır. Sonuç olarak ta IFN-α, aspirin ve DMAH tedavisi gebelerde güvenli olduğu ve gebelik sonuçlarını olumlu etkilediği görülmektedir.

🔖

Cite This Article

ACAR, K., BAĞLICAKOĞLU, M. (2009). Management of high risk essential thrombocythemia in pregnant with recurrent pregnancy loss. Selçuk Tıp Dergisi, Cilt: 25 - Sayı: 3, 167–170. https://ajindex.com/articles/319527

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112: 2199-204
  2. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007;110:485-9
  3. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 2009; 82: 350-3
  4. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol 2003; 16: 227-42
  5. Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Hematol 2009; 84: 636-40
  6. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293-306
  7. Liebelt EL, Balk SJ, Faber W, Fisher JW, Hughes CL, Lanzkron SM, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 259-366
  8. Thauvin-Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia 2001; 15: 1309-11
  9. Ballas SK, McCarthy WF, Guo N, DeCastro L, Bellevue R, Barton BA, et al. Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc 2009; 101: 1046-51
  10. Italia KY, Jijina FF, S C, Nadkarni AH, Sawant P, Ghosh K, et al. Exposure to Hydroxyurea During Pregnancy in Sickle-{beta} Thalassemia: A Report of 2 Cases. J Clin Pharmacol 2009 Oct 1. [Epub ahead of print]
  11. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45
  12. Doubek M, Brychtova Y, Doubek R, Janku P, Mayer J. Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia. Ann Hematol 2004; 83: 726-7
  13. Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokineti